相关实验视频

Updated: Jun 23, 2025

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on ¹⁸F-AV-1451

Published on: April 18, 2025

粉样蛋白-PET成像预测临床正常个体的功能衰退

Lisa Quenon^1,2, Lyduine E Collij^3,4,5, David Vállez Garcia^3,4

¹Institute of Neuroscience, UCLouvain, Brussels, Belgium. lisa.quenon@uclouvain.be.

Alzheimer's research & therapy

|June 17, 2024

概括

粉胺β (Aβ) 升高的PET扫描预测临床正常个体的功能下降. 特定的百叶状体 (CL) 值,CDR-SOB为41个,A-IADL-Q为28个,识别那些处于风险中的物种.

科学领域:

神经成像和生物标志物
阿尔茨海默氏症疾病研究研究
临床神经心理学临床神经心理学

背景情况:

胺β (Aβ) 信号的升高与临床正常 (CN) 个体的认知衰退有关.
在CN个体中,Aβ负担与日常生活活动下降之间的关联需要进一步研究.
预测功能衰退的最佳Aβ-PET百叶状体 (CL) 值尚未确定.

研究的目的:

调查由Aβ-PET百叶状体 (CL) 测量的Aβ负担与临床正常 (CN) 个体日常生活活动中的功能性下降之间的联系.
建立最佳的Aβ-PET CL值,以预测CN个体的功能衰退.

主要方法:

对欧洲粉样蛋白-PET成像AMYPAD-PNHS数据集的分析,包括1032名CN个体和228名具有可疑功能障碍的人.
用Centiloid (CL) 尺度评估了amyloid-PET,并将其分类为Aβ-,Aβ-中间/Aβ±和Aβ+组.
用临床痴呆症评分 (全球CDR,CDR-SOB) 和阿姆斯特丹日常生活仪器活动问卷 (A-IADL-Q) 来评估功能能力.

主要成果:

截面分析显示CL值与临床痴呆评分 (CDR) 结果相关.
纵向分析显示,基线CL值预测了CN参与者CDR-SOB和A-IADL-Q得分的未来变化.
预测下降的最佳门被确定为CDR-SOB的41个CL和A-IADL-Q的28个CL.

结论:

粉样蛋白-PET量化有效识别临床上正常的个体有功能衰退的风险.
已确定的Aβ-PET CL值可以帮助预测功能障碍的发展轨迹.

关键词:

粉样蛋白-PET是一种粉样蛋白.一个百分之形.功能性衰退功能性衰退日常生活中的工具性活动.临床前阿尔茨海默氏症临床前阿尔茨海默氏症

更多相关视频

Detecting Amyloid-β Accumulation via Immunofluorescent Staining in a Mouse Model of Alzheimer's Disease

Detecting Amyloid-β Accumulation via Immunofluorescent Staining in a Mouse Model of Alzheimer's Disease

Published on: April 19, 2021

Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis

Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis

Published on: February 28, 2021

相关概念视频

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

Positron Emission Tomography

Positron Emission Tomography

Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...